Abstract
Molecular biomarker testing is the standard of care for identifying potentially effective targeted therapies for patients with stage IV non-small cell lung cancer (NSCLC). Minority patients are less likely to undergo next-generation sequencing (NGS) and be enrolled in clinical trials compared to Non-Hispanic Whites (NHW). As such, frequencies of tumor biomarkers in minority populations in the United States are not well-defined and survival data for minority patients receiving targeted therapy is lacking.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
